<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510443</url>
  </required_header>
  <id_info>
    <org_study_id>18097</org_study_id>
    <secondary_id>ES0810FR</secondary_id>
    <nct_id>NCT02510443</nct_id>
  </id_info>
  <brief_title>Observational Study on Contraception With Essure in France</brief_title>
  <acronym>SUCCES II</acronym>
  <official_title>Survey on Use and Characteristics of Definitive Contraception With ESsure®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital André Mignot Centre Hospitalier de Versailles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using a very broad survey, the objective is to confirm the effectiveness of the Essure
      method, and to obtain more information on the conditions of use as well as on the methods
      used during the 3-month check-up, as well as the 12-month, 24-month and 5-year follow-up on
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective epidemiological survey to collect local real life data on patients
      under routine pratice
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2008</start_date>
  <completion_date type="Actual">November 25, 2016</completion_date>
  <primary_completion_date type="Actual">September 29, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients being satisfied with successful Essure procedure having no complications at 5 years</measure>
    <time_frame>At 5 years</time_frame>
    <description>Patient satisfaction will be assessed on a Likert scale. Complications are migration/expulsion of Essure, infection. Pregnancy will be measured at any time Point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with moderate or important pain when placement is performed</measure>
    <time_frame>At initial visit</time_frame>
    <description>Visual Analogue Scale (VAS) use to report the pain from 0 (no pain) to 10 (maximal pain). Moderate pain will range from 4 to 6 and important pain will range from 7 to 10 on the VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unsatisfied patients</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of satisfied patients at 3, 12 and 24 months</measure>
    <time_frame>At 3 ,12 and 24 months</time_frame>
    <description>Patients satisfaction assessed by Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of examinations by patients</measure>
    <time_frame>At 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of good insert position by implant and patients with success in final result of the procedure</measure>
    <time_frame>At 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of unsatisfied patients</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Possible causes of unsatisfaction : pregnancy, regret of the patient,migration/expulsion of Essure,or infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of examinations by patients</measure>
    <time_frame>At 3 months</time_frame>
    <description>Ultrasound transvaginale, radiography, or hysterosalpingography (HSG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with regrets</measure>
    <time_frame>At 12 months, 24 months and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2644</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>BAY1454032</arm_group_label>
    <description>All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESS305 (Essure, BAY1454032)</intervention_name>
    <description>Bilateral insert placement</description>
    <arm_group_label>BAY1454032</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients concerned are adult women wishing to undergo tubal sterilization for
        contraceptive purposes, in accordance with legal provisions, who had given their consent
        for collection of the data.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman ≥ 18 years old,

          -  Scheduled for Essure procedure

          -  Patient who has been given appropriate information about the study objectives and
             procedures and who has given her consent.

        Exclusion Criteria:

          -  Patients with contraindications as listed in the current Instruction For Use (IFU)
             will be excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Permanent contraception method</keyword>
  <keyword>Contraceptive device</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

